Related items

With the Foreign Subsidies Regulation (FSR) under review, now is the moment to ensure it delivers on its objectives without creating unnecessary complexity. The FSR plays an important role in addressing distortive foreign subsidies. However, its broad scope and resource-intensive procedures risk undermining its effectiveness. 

The current framework creates significant burdens for investors and contracting authorities managing public procurement processes. Changes to the Implementing Regulation alone would only provide limited value. Simplification will require targeted amendments to the primary legislation. 

Read more about proposed amendments that would help refocus the FSR on high-risk cases and support the EU’s competitiveness goals.

From Monday, 27 to Wednesday, 29 April, AmCham EU travelled to Paris, France and the European Parliament in Strasbourg, France for a series of meetings on EU financial services policy developments. The delegation engaged with representatives from French and European financial authorities, Members of the European Parliament, Accredited Parliamentary Assistants and Group Policy Advisers, to share business perspectives on the EU’s financial services agenda. Discussions focused on how to improve Europe’s competitiveness, deepen capital markets and create the right conditions for innovation in digital finance. Members also highlighted the need for more coherent and interoperable rules that reduce complexity while encouraging long-term investment through risk-based regulation.

On Tuesday, 28 to Wednesday, 29 April, AmCham EU travelled to the European Parliament in Strasbourg, France for a series of meetings with policymakers to discuss ongoing EU healthcare policy initiatives. The delegation met with Members of the European Parliament, Accredited Parliamentary Assistants and Group Policy Advisers, to discuss priorities for the EU’s health agenda. This included exchanges on how to strengthen Europe’s life sciences competitiveness and support resilient supply chains. Members also stressed the need for urgent action to simplify overlapping rules and reduce complexity. They underlined that proportionate, risk-based regulation is essential to support innovation. This approach can also help ensure timely patient access to medicines, medical technologies and diagnostics.